Hosted on MSN7d
Allurion’s weight loss balloon back on French market
Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...
TMCnet1d
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...
Nasdaq2d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
The Allurion Gastric Balloon is an investigational device in the United States. For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com. Sign up for ...
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the ...
Investopedia28d
Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
tripled Friday as the maker of the Allurion Gastric Balloon weight-loss device looked to take advantage of the booming obesity drug market. The company announced it would begin a study to see if ...
MassDevice8d
Allurion relaunches weight loss balloon in France
Allurion Technologies today announced the relaunch of its Allurion Balloon in France following regulatory clearance to resume ...
Investing3d
Allurion to study balloon and GLP-1 therapy combo
NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a medical device company with a market capitalization of $17.7 million focused on addressing obesity, announced today its plan to conduct a ...